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The gastrointestinal tract is the most common internal organ involved in systemic sclerosis. Any 
part of the gastrointestinal tract from the mouth to the anus can be affected. Despite extensive 
investigation the pathogenesis of gastrointestinal involvement in systemic sclerosis remains elusive.  
Dysmotiity of the gastrointestinal tract causes the majority of symptoms. Recent investigations have 
identified a novel mechanism in the pathogenesis of gastrointestinal tract dysmotility mediated by 
functional anti-muscarinic receptor autoantibodies. Furthermore, the role of microRNA in the 
pathogenesis of SSc gastrointestinal involvement is being intensively studied. Although treatment 
currently remains symptomatic, an improved understanding of novel pathogenic mechanisms may allow 
the development of potentially highly effective approaches including intravenous immunoglobulin and 















Systemic sclerosis (SSc) is a chronic systemic autoimmune disorder characterized by a severe 
and often progressive fibrotic process affecting the skin and numerous internal organs. Tissue 
fibrosis in SSc is accompanied by fibro-proliferative alterations in the microvasculature and 
various humoral and cellular immunological alterations leading to production of 
autoantibodies, tissue infiltration with chronic inflammatory cells and abnormalities in innate 
immunity.1 Gastrointestinal Tract (GIT) involvement occurs in greater than 90% of SSc patients.2 
Any part of the GIT from the mouth to the anus can be involved with dysmotility being the 
cardinal pathological abnormality contributing to the majority of symptoms.3 GIT involvement 
occurs in both the diffuse and limited cutaneous subsets of SSc. Patients may present with 
symptoms of SSc GIT involvement in the absence of cutaneous disease.  
Pathogenesis of SSc 
The exact mechanisms involved in SSc pathogenesis are not well understood. However, it is 
apparent that the clinical and pathologic manifestations of the disease are the result of three 
distinct processes: 1) Fibroproliferative vascular lesions of small arteries and arterioles, 2) 
fibrosis of skin and various internal organs induced by the increased production of various profibrotic 
growth factors such as transforming growth factor-β (TGF-β), connective tissue growth 
factor, and insulin-like growth factor, and 3) multiple alterations of innate, humoral and cellular 
immunity resulting in the accumulation of lymphocytes and macrophages in affected tissues 
and the production of numerous autoantibodies .8-12 Although the putative etiologic agent and 
the exact mechanisms involved have not been determined, recent studies have provided novel 
information about the early events in SSc pathogenesis. As a result of those studies it has been 
postulated that there is a sequence of alterations initiated by unknown etiologic factors in a 
genetically receptive host. The earliest events induce structural and functional endothelial cell 
abnormalities affecting selectively the microvasculature.13,14 These alterations cause increased 
production and release of numerous cytokines, chemokines and polypeptide growth factors 
that result in the recruitment of bone marrow-derived and circulating fibrocytes and in the 
phenotypic conversion of quiescent tissue fibroblasts, and of epithelial and endothelial cells 
into activated myofibroblasts, the cells ultimately responsible for the fibroproliferative 
vasculopathy and progressive tissue fibrosis.13,15,16 These alterations also result in chemokine 
and cytokine-mediated attraction of specific inflammatory cellular elements from the 
bloodstream and bone marrow to the affected tissues and in the activation of resident tissue 
macrophages resulting in the establishment of a chronic inflammatory process.17,18 This 
sequence of events is diagrammatically illustrated in Figure 1. 
Pathogenesis of GIT involvement in SSc 
The pathogenesis of GIT SSc is complex and poorly understood. There is a paucity of studies 
examining the etiology and pathogenesis of gastrointestinal manifestations in SSc.  
Fibroproliferative vasculopathy, immune dysfunction and fibrosis have been postulated as pathogenic 
mechanisms of GIT dysfunction and structural alterations in SSc 
(Figure 1). In the following sections we highlight the important role of each of these pathogenic 
processes in relation to the GIT involvement in SSc. Furthermore, we discuss the results of 
recent studies that have identified and explored unique and novel mechanistic pathways and 
have allowed to postulate a novel pathogenic model for GIT involvement in SSc. 
1. Vasculopathy 
Endothelial cell injury has been recently suggested to play a crucial role in SSc pathogenesis and 
results in increased production of reactive oxygen species and release of chemokines and 
growth factors, which lead to recruitment of inflammatory T and B cells and pro-fibrotic 
macrophages in the interstitium of affected tissues. Activated inflammatory cells and tissue 
hypoxia resulting from structural vascular damage cause further release of reactive oxygen 
species, cytokines and pro-fibrogenic mediators that propel the disease process.1 
Studies in GIT SSc have shown evidence of diminished mucosal blood flow in the duodenum and 
gastric antrum.22 Histological studies of the esophagus and stomach have demonstrated 
endothelial cell apoptosis, perivascular infiltrates and basement membrane thickening.23,24 
Vascular lesions such as gastric antral vascular ectasia (GAVE) and telangiectasia of the digestive 
tract are also representative of the diffuse vasculopathy affecting the GIT as illustrated in Figure 
2.25,26 
2. Humoral immunity 
Although the presence of numerous autoantibodies is one of the critical manifestations of SSc, 
the occurrence of functional autoantibodies capable of causing significant dysfunction of mouse 
colonic smooth muscle contraction by M3-R inhibition was not described until quite recently 
when Goldblatt and colleagues demonstrated the presence of such autoantibodies in the serum 
of SSc patients.27 Subsequent studies revealed that immunoglobulins isolated from the serum 
of SSc patients (SScIgGs) interfere with neurally (cholinergic) mediated contraction of the GIT. 
This was evidenced by the demonstration that SScIgGs caused specific attenuation of the 
simultaneous rat colonic contractile response and release of acetylcholine induced by electric 
field stimulation. SScIgGs were also found to abrogate the M3-R agonist-induced contractile 
response of rat colonic smooth muscle in a dose dependent manner. 28,29 Most recently, it was 
shown that SScIgGs lead to GI cholinergic dysfunction by binding at the M3-R on the GI smooth 
muscle and the myenteric cholinergic neurons of the rat colon. (Figure 3) Further analysis 
revealed that IgG’s isolated from SSc patients early in their disease course bind with greater 
intensity to the myenteric neurons. As the disease duration increases, there is progressive 
increase in binding at both the smooth muscle and myenteric neurons. Of substantial 
therapeutic significance were the observations that the neural and myogenic effects of the 
SScIgGs were consistently and reproducibly abrogated by the administration of pooled human 
intravenous immunoglobulin (IVIG) and its antigen binding fragment F(ab’)2 .30 
3. Cell-mediated immunity (CMI) 
Numerous studies have demonstrated strong evidence for the role of CMI in SSc.31-33Recent 
studies have shown that alterations in CMI are important participants in GIT involvement in SSc. 
Gastric biopsy specimens have demonstrated accumulation of immune cell infiltrates mainly 
consisting of CD4+ T lymphocytes with a pronounced increase in the CD4+/CD8+ T cell ratio.34 
SSc in general has a predominant Type 2 helper (Th2) polarization of CD4+ T cells.1 IL-4 causes 
naïve CD4+ cells to differentiate into Th2 cells by downstream activation of STAT6 and GATA3, 
which lead to further production of IL-4 and IL-13, the classic Th2 cytokines.35 IL-4 in a positive 
feedback amplifies its own response and also up-regulates humoral immunity by inducing 
immunoglobulin production and isotype switching (Figure 1). IL-13 along with IL-6 released 
from various cells are pro-fibrotic cytokines that cause fibrosis by direct pro-fibrotic effects as 
well as by activating TGF-β. 33 The presence of increased CD4+ cells in gastric biopsy specimens 
could be responsible for excessive production of pathogenic autoantibodies and the extensive 
GIT fibrosis, as described above. 
4. Fibrosis 
Fibrosis disrupts the normal tissue architecture and leads to a non-functioning GIT. TGF-β 
produced by activated fibroblasts and immune cells leads to extensive fibrosis by Smaddependent 
and Smad-independent pathways36, and in conjunction with endothelin-1 (derived 
from endothelial cells) participates in the conversion of fibroblasts into myofibroblasts.11,16 
Myofibroblasts produce excessive fibrillar type l and type lll collagen along with other 
extracellular matrix components, initiate expression of α-smooth muscle actin and are the cells 
ultimately responsible for the fibrotic process.9,37-39 Gastric wall biopsies of SSc patients show 
generalized patchy fibrosis, increase deposition of type l and type lll collagen in the muscularis 
mucosae, submucosa and muscularis propria, and strong expression of fibrogenic cytokines 
including TGF-β, connective tissue growth factor and the myofibroblast marker α-smooth 
muscle actin. (Figure 4)40 As collagen has a higher elastic modulus than smooth muscle, its 
deposition in the intestinal wall leads to increased stiffness, subsequently causing impaired 
muscle contractility. Furthermore, increased tissue stiffness has been recently shown to 
represent a potent stimulus for further fibrotic deposition.41,42Besides fibroblasts, telocytes 
(peculiar type of stromal cells with long cytoplasmic processes) essential for extracellular 
matrix scaffolding are damaged and severely reduced in fibrotic areas of gastric muscle in SSc.43 
Recent studies have also highlighted the role microRNA (miRNA) in SSc pathogenesis. 
Differentially expressed miRNAs that target both inflammation and fibrosis have been identified 
in SSc.44,45 These miRNAs may be either anti- or profibrotic. Of these miRNAs, the ones that 
modulate TGF-β signaling and the expression of related genes encoding collagens, 
metallopeptidases, and integrins are the most significant. The miR-29 family has been 
extensively studied in relation to SSc.46 Indeed, miR-29, which targets collagen gene expression 
and regulates fibrosis, has been shown to be severely reduced in SSc skin biopsies47 and 
reduced levels of miR-29 have been suggested to lead to increased tissue deposition of 
collagen. 
Novel developments in the Pathogenesis of SSc GIT involvement 
We recently proposed that GIT dysfunction in SSc is a staged process beginning with 
neuropathy and progressing to myopathy, with eventual fibrosis.30 The initial neuropathic 
damage leads to disrupted contraction with normal amplitude in manometric assessment, 
which is followed by a substantial reduction in amplitude of contractions signifying the 
development of myopathy.30 The earliest evidence for neuropathy was obtained in a study that 
showed contractile response of the esophageal smooth muscle of SSc patients to the direct 
acting muscarinic agonist methacholine but not to edrophonium, which acts indirectly.26 These 
and numerous subsequent studies suggested that in the early stages of SSc GIT involvement 
circulating M3-R autoantibodies block cholinergic neuro-transmission by inhibition of 
acetylcholine release at the myenteric cholinergic nerves (neuropathic damage), and that 
progression of the disease leads to myopathy via inhibition of acetylcholine action at the 
gastrointestinal smooth muscle cell.30 Some of these studies further suggested a temporal 
increase in binding of SScIgGs to the neural and myogenic M3-R with disease duration, 
observations that may account for the progressive nature of GIT involvement in SSc. The 
demonstration of autoantibody-mediated inhibition of neurotransmission provides a cogent 
rationale to the well-demonstrated observations that SSc patients may develop GIT 
manometric abnormalities long before the occurrence of histological changes in the GIT. As 
acetylcholine is the principal excitatory neurotransmitter in the GIT, inhibition of its release 
results in the absence of response of the smooth muscle in the GIT and its inability to contract 
in response to physiological stimuli. However, intestinal dysfunction at this stage is still 
reversible if the M3-R autoantibodies can be removed from the plasma or neutralized. 
Subsequently, loss of GIT contractile function may be the result of disuse muscle atrophy and 
progressive SSc related tissue fibrosis. (Figure 4) Once fibrosis ensues the smooth muscle is 
unable to respond to any type of external stimuli and treatment of dysmotility at this stage is 
futile. The fibrosed and dysfunctional GIT leads to reflux of gastric acid contents into the 
esophagus, a dilated and non compliant stomach, overgrowth of bacteria in the small intestine, 
colonic dilatation and a non-functional internal anal sphincter, alterations that manifest 
clinically as Barrett’s esophagus, gastroparesis, severe malabsorption, and fecal incontinence, 
respectively. Increased accumulation of fibrillary collagens and reduced expression of matrix 
metalloproteinase-1 along with GIT dysmotility lead to development to wide mouth diverticula, 
which have been reported in the esophagus, small intestine and the colon.48 The pathogenesis 
of GAVE and vascular ectasia in the small intestine has been suggested to be analogous to the 
vasculopathy responsible for the cutaneous and other vascular manifestations of SSc. (Figure 3) 
IVIG could potentially have multiple beneficial 
effects in SSc not only by anti-idiotypic mediated neutralization of muscarinic autoantibodies 
but also by causing reduction of pro-fibrotic cytokines or by counteracting the deleterious 
effects of anti-fibroblast or anti-endothelial cell circulating antibodies. IVIG is relatively safe 
compared to immunosuppression and has been shown to be beneficial in halting progression of 
GI symptoms in observational studies and to reverse cholinergic dysfunction induced by M3-R 
autoantibodies in vivo.29,30,103-105 Targeting miR-29 by anti-miRs, which are chemically modified 
oligonucleotides, is another promising therapeutic option in the future.46,106 However, rigorous 
studies are needed before patients can be benefited from these novel interventions. 
CONCLUSION 
GIT involvement is the most common non-cutaneous organ system involved in SSc and is 
associated with substantial morbidity and mortality. Our current understanding of the 
pathogenesis and treatment of this entity is still far from complete, owing to the limited 
number of studies that have focused on histo-pathological, cellular and molecular changes in 
the GIT. Autoantibody mediated dysmotility offers a new avenue for further research into the 
pathogenesis and treatment of gastrointestinal SSc. Moreover, there is lack of non-invasive 
tests or biomarkers, which can identify patients who are at high risk for development of GIT 
manifestations. Early identification and symptomatic treatment of patients is crucial until more 
targeted and effective disease-modifying therapeutic approaches become available. Improved 
understanding of the pathogenesis of GIT manifestations of SSc employing focused and 
intensive cellular and molecular studies, research endeavors aimed at identification of novel 
disease biomarkers, and extensive efforts to develop personalized medical therapies should 
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Figure 1: Pathogenesis of SSc: Unknown environmental factors in a genetically susceptible host 
trigger initial endothelial cell injury. This results in release of reactive oxygen species, 
chemokines, cytokines, and growth factors. The local cytokine milieu leads to recruitment and 
activation of chronic inflammatory cells, including T- and B-lymphocytes and macrophages. Bcells 
evolve into plasma cells that produce M3-R antibodies, which occupy the extracellular 
loop-2 of the M3-R on the intestinal smooth muscle and prevent acetylcholine released from 
the synaptic terminal to act on the receptor. The CD4+ T cells under influence of IL-4 
differentiate into Th2 subtype. Th2 cells secrete pro-fibrogenic cytokines IL-4 and IL-13, which 
along with IL-6 stimulate TGF-β production. Fibroblasts are activated into myofibroblasts by 
action of TGF-β. Myofibroblasts produce excess collagen, which causes structural damage and 
fibrosis, distorting the normal architecture of the tissue, leading to dysmotility. 
Figure 2: SScIgG binding to colon: Transverse section of rat colon demonstrating specific 
binding of SScIgG to the smooth muscle and myenteric plexus as evidenced by increase 
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SScIgG binding to colon: Transverse section of rat colon demonstrating specific binding of SScIgG to the 
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